Artikelen door HollandBIO

Cergentis appoints new CEO and Board members

Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the appointment of Joris Schuurmans as Chief Executive Officer and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergentis’ growth potential. Incoming CEO Joris Schuurmans has […]

, , ,

Dutch Life Sciences Trend Analysis: Record year of venture financing

Biotechgate, the leading global biotech database, presents the annual Trend Analysis Report for the Dutch life sciences sector. The report shows a stable amount of life sciences companies and a sector which has grown in maturity. Biotech companies were successful in attracting venture capital; 2019 is a record year for venture financing. Dutch biotech companies […]

Kiadis announces first patient enrolled with off-the-shelf K-NK cells

Kiadis Pharma, a clinical stage biopharmaceutical company, and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital (OSUCCC-James), today announced that the first patient has been enrolled and treated in a phase I, first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia (“R/R AML”) with off-the-shelf Natural Killer (“NK”) cells […]

BISC Global opens an office in San Francisco

BISC Global is pleased to announce the opening of a new branch in South San Francisco, California. The new location complements the global presence with its current offices in Belgium, Boston and Switzerland. “We are thrilled to be expanding our footprint into the technology hub that is the Bay area” said Maarten Braspenning, CEO of […]


Update wijziging Wgp en modernisering GVS

De herijking van de maximumprijzen op grond van de Wet geneesmiddelenprijzen (Wgp) per 1 oktober 2020 gaat gepaard met twee mitigerende maatregelen, zo laat VWS-minister van Rijn de Kamer weten in een Kamerbrief. Met deze maatregelen beoogt de minister risico’s op beschikbaarheidsproblemen te verkleinen en de geneesmiddelenmarkt, gezien de COVID-19-crisis, niet extra te belasten. De […]


Access to COVID-19 Tools (ACT) Accelerator publishes consolidated plans

No-one is safe until everyone is safe. To end the ongoing COVID-pandemic, a groundbreaking global response is required. By drawing on the experience of leading global health organizations, governments, businesses, civil society and philanthropists the Access to COVID-19 Tools (ACT) Accelerator aims to accelerate the development, production, and equitable access to COVID-19 diagnostics, therapeutics, and […]

Hansa Biopharma receives positive CHMP opinion for Idefirix for kidney transplant in EU

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending conditional approval of IdefirixTM (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive […]

BioGeneration Ventures closes BGV IV fund at €105 million

BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund’s original target. The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, […]


Scenic Biotech Awarded €3.1 million Innovation Credit

Scenic Biotech, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has been awarded a €3.1 million Innovation Credit from the Dutch Government. The funds will be used to advance the Company’s lead CD47/QPCTL immuno-oncology program […]